The 3Q24 update from Compass Pathways surprised the market with news that timelines for the group’s COMP360 Phase 3 trials had been extended. The company is reducing staff headcount by ~30% and ...
Forbes contributors publish independent expert analyses and insights. Dr. Lance B. Eliot is a world-renowned AI scientist and consultant. In today’s column, I am continuing my special series covering ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback